Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EBIT (2018 - 2025)

BioNexus Gene Lab's EBIT history spans 8 years, with the latest figure at -$702509.0 for Q3 2025.

  • For Q3 2025, EBIT rose 47.48% year-over-year to -$702509.0; the TTM value through Sep 2025 reached -$2.3 million, down 161.02%, while the annual FY2024 figure was -$1.6 million, 39.32% up from the prior year.
  • EBIT for Q3 2025 was -$702509.0 at BioNexus Gene Lab, down from -$611293.0 in the prior quarter.
  • Across five years, EBIT topped out at $372641.0 in Q3 2021 and bottomed at -$2.5 million in Q3 2023.
  • The 5-year median for EBIT is -$79028.0 (2024), against an average of -$280783.7.
  • The largest annual shift saw EBIT skyrocketed 6713.91% in 2021 before it tumbled 3777.19% in 2023.
  • A 5-year view of EBIT shows it stood at $201063.0 in 2021, then plummeted by 161.02% to -$122689.0 in 2022, then surged by 310.09% to $257754.0 in 2023, then crashed by 261.48% to -$416220.0 in 2024, then tumbled by 68.78% to -$702509.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's EBIT are -$702509.0 (Q3 2025), -$611293.0 (Q2 2025), and -$618418.0 (Q1 2025).